In glioma, CACYBP appears to have an oncogenic role by enhancing proliferation and reducing apoptosis via downregulation of p53 and p21, alongside activation of Akt, β-catenin, and ERK1/2 [35, 36]. This evidence concerns the gene MAPK3 and central nervous system cancer.